The Latest

The Moment of Clarity Every transformation begins with a reckoning. For healthcare AI, that reckoning has arrived. After years of exuberant promise — diagnostic precision, predictive power, automated insight — the industry now faces a harder question: can we prove any of it?The market correction underway is not a failure of technology, but a recalibration of credibility. The gap between AI’s potential and its performance has exposed the one truth that medicine has always known: evidence must be verifiable to be trusted.From Collapse to CalibrationThe collapse of confidence in healthcare AI has forced institutions to confront the limitations of opportunistic data and opaque models. This disillusionment, though painful, is constructive.It signals a collective shift from experimentation to accountability. Hospitals are implementing data provenance frameworks. Regulators are standardizing AI validation criteria. Investors are favoring platforms that demonstrate longitudinal evidence rather than short-term performance.What looks like contraction is, in reality, calibration — the transition from unverified enthusiasm to regulated maturity.The Rise of Evidence-Grade DataThe future will not be defined by better algorithms but by evidence-grade data — datasets with known origin, stable structure, and continuous verification. Circle’s architecture operationalizes this standard:Observational Protocols capture real-world evidence in structured, interoperable form.Provenance tracking ensures every record’s lineage is auditable.Federated design allows institutions to contribute without losing control.This transforms healthcare data from anecdotal exhaust into a regulated asset class — reusable, defensible, and valuable.Operational Efficiency Through ProofFor hospitals, proof-ready data reduces compliance costs and accelerates clinical validation. For researchers, it allows reproducible studies across networks. For payers and regulators, it delivers verifiable evidence without the need for redundant auditing.The same mechanisms that make AI trustworthy also make it efficient. Verification eliminates rework. Provenance reduces friction. Trust becomes not an overhead expense, but an operational advantage. The Economic ReorderingAs verification becomes the new currency, the healthcare data economy will reorganize around credibility.Vendors with unverifiable datasets will see valuations decline.Networks with validated data architectures will attract capital and partnerships.Institutions capable of continuous compliance will set the standards others must follow.The winners of this transition will be those who treat trust as infrastructure — not as a message, but as a measurable system property.Strategic OutcomeThe AI reckoning is not an end — it’s a beginning. Medicine’s next digital chapter will not be written in code, but in proof: data that can be traced, tested, and trusted across its entire lifecycle. Circle’s model offers the blueprint — a verified data ecosystem where clinicians, innovators, and regulators operate on shared evidence rather than belief. For the first time, the industry can build intelligence that is not just powerful, but accountable. That shift — from confidence to credibility — is the real opportunity of the reckoning.

MOTIV™ – the MSK real-world evidence collaboration between RegenMed and OREF – is off to a strong start. The initial MOTIV™ Observational Protocol (OP) is based upon the mandated CMS TKA PRO PM, but also collects product, surgical technique, pain management, and other real-world data. The OREF expert-reviewed OP was co-authored by Doctors Andrew Wickline and John Mercuri. WCG Clinical Services has issued its Certificate of Action confirming that the generation of Circle Datasets pursuant to that OP is exempt under 45 CFR 46.104(d)(4). Orthopedic surgeons from around the country, and representing over 2,000 TKAs annually, have already joined as Circle Members and begun enrolling Cases. Many more have indicated their intention to join. Last week’s initial Circle Hour brought together current and interested Circle Members. Topics included positive feedback on clinician and patient experience, benefits of national collaboration on TKA topics of common interest, and the opportunities for publication and Circle Dataset licensing. RegenMed and OREF will be hosting another Circle Hour at the Academy meeting in New Orleans in early March. The FDA TEMPO and CMS ACCESS programs are prioritizing fit-for-purpose, verifiable real-world evidence for several major therapeutic areas, including MSK. Circle Datasets not only meet these requirements, they do so with excellent physician UX, collaboration and ethical financial participation. Please contact Alyssa Johncola or Erika Deleon to learn more.

The physician’s role in the 2026 healthcare economy has been paradoxically diminished by the very systems designed to support it. As administrative burdens reach historic levels and corporate consolidation continues to prioritize short-term margins, clinical autonomy is being systematically eroded. However, a new paradigm is emerging: Professional Sovereignty. This model recognizes that the clinical intellect and the resulting real-world evidence (RWE) generated during a patient encounter are high-value assets. By leveraging structured "Circle Datasets"—closed-loop systems that capture diagnosis, treatment, and longitudinal outcomes—physicians can transition from being commoditized "cogs" in a corporate machine to being the owners of a tech-enabled clinical asset. The Crisis of Autonomy: Burnout as a Structural SymptomThe push for Professional Sovereignty is a direct response to the structural failure of traditional employment and private equity models.The Administrative Burden: In 2026, administrative tasks remain a primary driver of clinician burnout. Recent data indicates that nearly 90% of physicians report that processes like prior authorization significantly increase stress.The "Time-to-Care" Deficit: For every hour spent in direct patient care, clinicians frequently spend up to two hours on documentation and administrative desk work.The Impact of Private Equity (PE): Surveys conducted by the American College of Physicians (ACP) show that physicians in PE-owned practices report lower professional satisfaction and less autonomy compared to their independent counterparts. PE firms often focus on short-term revenue generation, sometimes paring down services or increasing debt loads on acquired practices.Workforce Stability: Physician turnover in PE-acquired practices has been shown to increase from 5% to over 20% in the three years following acquisition, as younger physicians move to reclaim their clinical freedom.The Data Gold Rush: Why Clinical Intellect is a Monetizable AssetWhile clinicians are struggling under administrative weight, the market for the data they produce is surging. The global real-world evidence (RWE) solutions market was valued at $20.03 billion in 2025 and is projected to reach $22.3 billion by the end of 2026.The Value Proposition of Provider DataHealthcare providers occupy a unique position as the primary collectors and aggregators of high-fidelity clinical data. Unlike administrative claims data, which serve as mere proxies for health, clinical datasets provide the granular "ground truth" required for:Life Sciences and Biopharma: Supporting drug development, accelerating product pipelines, and demonstrating therapy value in real-life settings.Regulatory Oversight: Providing market surveillance and detecting adverse events with higher precision than traditional reports.Precision Medicine: Guiding personalized treatment plans based on genomic and biomarker data.Mechanics of Monetization: From Overhead to RevenueData monetization represents a structured, compliant pathway for physicians to produce measurable economic benefits from their existing clinical knowledge. There are two primary avenues for this:Indirect Monetization: Operational Efficiency‍By using structured datasets to gain real-time insights, practices can reduce waste and optimize resource allocation.Resource Optimization: Monetization strategies help practices understand equipment and personnel utilization, allowing for more strategic staffing.Clinical Decision Support: Well-managed data environments reduce diagnostic errors—which currently occur in roughly 11.1% of cases—thereby lowering liability risks.Direct Monetization: Data-as-a-Service (DaaS)‍Direct monetization involves generating revenue through the licensing of aggregated, de-identified datasets to external stakeholders.License Fees: Physicians can participate in data marketplaces, offering curated datasets (e.g., pharmacy trends, oncology outcomes) to trusted partners.Insight-as-a-Service (IaaS): Instead of selling raw data, providers can apply AI analytics to generate specific predictive models or decision-support tools and sell access to those outputs.Revenue Share: Innovative models allow clinicians to retain a significant portion of the resulting licensing fees—up to 85% in some sovereignty-focused frameworks—transforming their daily practice into a recurring revenue stream.Circle Datasets: The Infrastructure for SovereigntyTo achieve true Professional Sovereignty, a clinician must move beyond legacy Electronic Health Records (EHRs), which are often designed for billing rather than clinical accuracy. Circle Datasets provide the necessary strategic infrastructure.Closed-Loop Integration: These systems integrate clinical diagnosis, specific treatment data, and long-term functional outcomes into a single, high-fidelity record.Regulatory-Grade Integrity: By ensuring that data meets the 2026 standards for "Proven Medical Accuracy," Circle Datasets are ready for federal audits and high-stakes research without the artifacts found in administrative coding.Self-Sovereign Data (SSD) Models: Sovereignty-focused tools allow the individual provider or medical group to maintain full ownership and control over their data, including the ability to manage access permissions and ethically license its use.The Strategic Shift: From Service Business to Tech-Enabled AssetThe financial implication of Professional Sovereignty is most evident in the valuation of the medical practice.Breaking the Multiplier Ceiling: A traditional medical practice is typically valued as a "service business," fetching multiples of 6–8x EBITDA. By demonstrating a proprietary data asset, that valuation can shift to 12–15x EBITDA, reflecting the value of a "tech-enabled asset".The "Liability Shield": Verified outcomes data serves as a defense against legal claims and can be used to negotiate lower malpractice and insurance premiums.Independence and Sustainability: Modern efficiency tools—including cloud-based EHRs and automated management solutions—have lowered the barriers to entry for private practice, making independence a sustainable alternative to the "cog-in-the-wheel" employment model.ConclusionProfessional Sovereignty is not merely a nostalgic return to independent practice; it is a forward-looking strategy that aligns the physician’s clinical intellect with the demands of the 2026 data economy. By utilizing Circle Datasets to capture and monetize high-trust evidence, physicians can reclaim their autonomy, build significant non-dilutive revenue, and protect their professional legacy from the commoditizing forces of corporate consolidation. In the new era of healthcare, those who own the data own the future of medicine.

Executive Summary: The Rise of the Clinical ArchitectThe 2026 regulatory environment, dominated by the Centers for Medicare & Medicaid Services (CMS) Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model, has fundamentally redefined the role of clinical leadership. In the legacy fee-for-service (FFS) era, financial success was a function of volume and coding accuracy. In the current era of Outcome-Aligned Payments (OAPs), financial performance is a direct result of "Outcome Engineering"—the rigorous, data-driven design of clinical pathways specifically calibrated to achieve measurable physiological and functional targets. For executives in Physician Management Organizations (PMOs) and specialty networks, the clinical pathway is no longer just a quality tool; it is the primary driver of the organization’s financial solvency and market valuation.The ACCESS Model: A Binary Financial LandscapeTo understand the necessity of Outcome Engineering, one must first master the high-stakes financial mechanics of the ACCESS model launched in July 2026.The 50% Reconciliation RiskUnlike previous value-based experiments, ACCESS introduces a stark 50/50 payment split. Participating organizations receive an upfront portion of the OAP to fund the technology and staff required for continuous management. However, the remaining 50% is withheld and reconciled based on a clinical track's specific outcome attainment rates.The Performance Threshold: CMS sets a minimum performance threshold—the percentage of an enrolled patient panel that must meet defined clinical outcomes.Increasing Stringency: This threshold is not static; it increases annually throughout the 10-year test period, requiring organizations to continuously refine their engineering to maintain margins.Substitute Spend ImpactFinancial performance is further weighted by "Substitute Spend"—the reduction in avoidable high-cost services like emergency room visits or inpatient stays. A clinical pathway that successfully engineers an outcome but fails to reduce total cost of care risks a reconciliation penalty of up to 25%. The Engineering Process: Designing for TargetsOutcome Engineering replaces the "episodic encounter" with a "continuous control loop". This involves three specific design phases:Signal Acquisition and Baseline Precision‍Engineering begins with the collection of high-fidelity baseline data. Under the Veracity Mandate, administrative codes are insufficient. Pathways must utilize:Remote Patient Monitoring (RPM): Continuous biometric signals (blood pressure, glucose, heart rate) to establish a true physiological baseline.Standardized PROMs: Validated Patient-Reported Outcome Measures, such as the KOOS Jr for musculoskeletal health or PHQ-9 for behavioral health, to quantify a patient's functional starting point.Guideline-Informed Intervention Sequencing‍Once the baseline is established, the pathway must sequence interventions based on the highest probability of hitting the target biomarker within the performance window.CKM Tracks: For hypertension, this may mean an engineered sequence of lifestyle coaching, followed by a fixed-dose combination of two first-line agents, monitored weekly via cellular-connected cuffs to ensure a target of <130/80 mmHg is reached quickly.MSK Tracks: For chronic pain, the pathway might prioritize sensor-based physical therapy and behavioral support over immediate orthopedic imaging, justifying the delay of high-cost "Substitute Spend" (surgeries) through documented functional recovery.Variance Detection and Rapid Remediation‍The hallmark of a well-engineered pathway is its ability to detect "variance"—any deviation from the expected clinical trajectory—long before the patient or provider recognizes a crisis.AI-Driven Alerts: Automated oversight tools identify non-compliance or physiological worsening, triggering an immediate nurse-led or asynchronous digital intervention.Reconciliation Defense: By remediating variance in real-time, the organization ensures that the maximum number of patients meet the year-end The Business Case: Valuation MultipliersTransitioning to Outcome Engineering is more than a clinical shift; it is a financial transformation.Margin Preservation: Standardized pathways reduce the "fully loaded cost" of care by eliminating waste and ensuring that expensive interventions (like skin substitutes or surgery) are only used when evidence supports their success.Tech-Enabled Asset Status: Organizations that can prove their clinical veracity through audit-ready ground truth move away from the low multiples of "service businesses" (6–8x EBITDA) and toward the high multiples of "tech-enabled assets" (12–15x EBITDA).Regulatory De-risking: By using automated, explainable systems to hit ACCESS targets, executives build an immutable audit trail that protects against the proactive federal scrutiny and revenue stoppages now common in 2026. ConclusionOutcome Engineering is the new standard for healthcare sustainability. In the 2026 ACCESS landscape, the winners will be those who treat clinical care as a precise engineering discipline rather than a series of disconnected episodes. By designing pathways that deliberately hit physiological and functional targets, healthcare leaders can secure their financial performance, minimize reconciliation risk, and provide the verifiable clinical accuracy that the Veracity Mandate demands.

Executive Summary: Converging Regulation and ReimbursementThe traditional paradigm of healthcare innovation—a linear progression from bench to bedside—is fundamentally incompatible with the iterative nature of digital health. Historically, medical device manufacturers have faced a "chicken-and-egg" dilemma: they require real-world outcomes data to secure regulatory clearance and payer uptake, but they cannot generate that data without the very clearance and reimbursement they seek. In 2026, the federal government has addressed this structural gridlock through the coordinated launch of the Centers for Medicare & Medicaid Services (CMS) Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model and the Food and Drug Administration (FDA) Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot. By aligning payment incentives with regulatory flexibility, these programs create a synergistic loop that allows digital health tools to enter the clinical workflow sooner, generating the high-trust evidence required for both long-term solvency and market authorization. CMS ACCESS: The Demand-Side Reimbursement CatalystLaunching on July 5, 2026, the ACCESS model represents a ten-year national test of an alternative payment methodology designed to replace episodic fee-for-service (FFS) with Outcome-Aligned Payments (OAPs).Mechanics of Outcome-Aligned PaymentsUnder ACCESS, Medicare Part B providers receive fixed, recurring payments for the continuous management of beneficiaries with chronic conditions.Payment Structure: Participating organizations receive up to 50% of the total OAP in upfront installments to support the operational costs of technology-enabled care. The remaining 50% is withheld and subject to reconciliation based on clinical performance.Performance Metrics: Payments are tied to "Outcome Attainment Rates"—the percentage of a patient panel that meets specific, guideline-informed targets compared to each patient's unique baseline.Focus Areas: The model initially targets four high-prevalence clinical tracks: Early Cardio-Kidney-Metabolic (eCKM), Cardio-Kidney-Metabolic (CKM), Musculoskeletal (MSK), and Behavioral Health (BH).By rewarding clinical results rather than service volume, ACCESS creates a direct financial incentive for providers to adopt digital therapeutics (DTx), remote patient monitoring (RPM), and wearable devices that can drive measurable physiological changes. FDA TEMPO: The Regulatory Supply SandboxRecognizing that digital health devices often improve through rapid iteration in real-life settings, the FDA’s Center for Devices and Radiological Health (CDRH) launched the TEMPO pilot as a voluntary "regulatory sandbox".Enforcement Discretion and Real-World EvidenceTEMPO allows selected U.S.-based manufacturers of digital health tools to deploy their devices within ACCESS-participating organizations before obtaining full 510(k) or De Novo marketing authorization.Regulatory Flexibility: The FDA may exercise "enforcement discretion" for certain premarket and investigational device requirements, provided the device is used under clinician supervision and meets strict safety guardrails.Structured Data Collection: In exchange for earlier market entry, manufacturers must commit to sharing real-world data (RWD) with the FDA. This data is used to generate the Real-World Evidence (RWE) necessary to support future formal marketing submissions.Iterative Discussions: The pilot utilizes "sprint" discussions—focused interactions aimed at reaching agreement on endpoints and analysis plans within defined timelines (typically 45 days)—leveraging the framework of the Total Product Life Cycle Advisory Program (TAP).The Synergistic Loop: Breaking the Innovation BarrierThe true strategic value for healthcare executives lies in the interplay between these two programs. The alignment of ACCESS and TEMPO eliminates the historical gap between regulatory clearance and reimbursement.Reimbursement Demand: The ACCESS model creates a cohort of providers who are financially motivated to use technologies that reduce biomarkers (like HbA1c or blood pressure) or improve functional outcomes.Regulatory Supply: The TEMPO pilot provides a pathway for manufacturers to supply these clinicians with tools that are not yet cleared but are clinically promising.High-Trust Evidence Generation: Clinicians test clinical hypotheses in the context of "everyday" practice. The data generated serves a dual purpose: it fulfills the clinical outcome reporting requirements for CMS payment reconciliation and provides the FDA with the real-world performance data needed for authorization.Market Advantage: Companies participating in the synergistic loop gain a multi-year lead over competitors trapped in the traditional, slow RCT-to-reimbursement cycle. Clinical Tracks and Outcome TargetsThe synergy is most potent in clinical areas where technology can bridge the gap between physician visits.Technical Mechanics: Interoperability and ConsentTo ensure the integrity of the synergistic loop, the models mandate high standards for data architecture and patient protection.Mandatory Interoperability: ACCESS participants must share standardized clinical updates electronically through FHIR®-based APIs or Health Information Exchanges (HIEs). This ensures that "ground truth" clinical data flows seamlessly to primary care practitioners (PCPs) and regulators.Enhanced Beneficiary Consent: Providers using TEMPO devices must obtain specific consent from patients, informing them that the device is part of an FDA pilot and that their data will be shared with the agency for performance monitoring.Co-Management Incentives: To prevent care fragmentation, CMS offers a new co-management payment (approximately $30 per use) to PCPs who review and coordinate care updates from ACCESS participants. Strategic Implications for ExecutivesFor healthcare leaders, the ACCESS-TEMPO alignment necessitates a shift in organizational strategy:For MedTech Manufacturers: Transition from seeking "clearance first" to seeking "pilot partnership". The ability to generate RWE while simultaneously earning revenue via ACCESS-participating partners is a significant de-risking event for investors.For Provider Organizations (MSOs): The 50% performance withhold in ACCESS creates a substantial reconciliation risk. To mitigate this, MSOs must adopt high-fidelity tracking tools that provide real-time visibility into whether a patient is hitting their outcome targets before the reconciliation window closes.For Payers and Self-Insured Employers: These models provide a framework for evaluating digital health tools based on actual "Substitute Spend" reduction (e.g., fewer ER visits or delayed surgeries) rather than theoretical benefit. ConclusionThe alignment of CMS ACCESS and FDA TEMPO signals the end of "proxy-based" healthcare. In this new era, market advantage is secured not by those who perform the most procedures, but by those who can provide verifiable, technology-enabled proof of clinical success. By entering the synergistic loop, healthcare stakeholders can transform clinical encounters into high-trust datasets, driving both patient health and business valuation in the 2026 regulatory environment.